Singula Bio is a seed-stage biotechnology company that was spun out of the University of Oxford. The company is focused on developing novel neoantigen-based cell therapies for patients with solid tumours. Singula Bio aims to become a world leader in providing individualised cell therapies for cancer. We have developed immunological, medical, surgical and computational technologies to develop selective therapies for difficult-to-treat solid malignancies such as ovarian cancer.